Therapeutic management of hematological malignancies in elderly patients. Biological and clinical considerations
| Autor: | E. Pasqualoni, Di Leonardo G, N. Furia, Di Simone S, Dennis Quaglino |
|---|---|
| Rok vydání: | 1998 |
| Předmět: |
Oncology
Melphalan Aging medicine.medical_specialty Antineoplastic Agents Hormonal medicine.medical_treatment Diagnosis Differential Prednisone hemic and lymphatic diseases Internal medicine medicine Humans Antineoplastic Agents Alkylating Multiple myeloma Chemotherapy business.industry Macroglobulinemia Waldenstrom macroglobulinemia Combination chemotherapy medicine.disease Hematologic Diseases Drug Therapy Combination Plasmapheresis Waldenstrom Macroglobulinemia Geriatrics and Gerontology Multiple Myeloma business medicine.drug |
| Zdroj: | Aging Clinical and Experimental Research. 10:5-12 |
| ISSN: | 1720-8319 1594-0667 |
| DOI: | 10.1007/bf03339628 |
| Popis: | Following recent data on multiple myeloma (MM) in the literature, a possible model of myeloma development, involving different cytokine signals, is advanced, and the prognostic significance of two principle staging systems is evaluated. Different therapeutic approaches to MM have been employed, consisting of either treatment with only melphalan and prednisone, or combination chemotherapy, especially in patients with a poor prognosis. However, for the initial therapy, melphalan plus prednisone in doses that compensate for individual variation in drug absorption still appears the best choice in the vast majority of MM patients. The main clinical and hematological features which distinguish Waldenström's macroglobulinemia from MM are described, as are the criteria which should be used in choosing the most appropriate treatment based, when necessary, on chemotherapy with standard alkylating agents, as well as on the new nucleoside analogues, and repeated courses of plasmapheresis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink